Clinical validation of a new dimeric inhibin-A assay suitable for second trimester Down's syndrome screening

Journal of Medical Screening

Volumn 8, Issue 1, 2001, Pages 2-7

  Knight, G J ^a,c   Palomaki, G E ^a   Neveux, L M ^a   Haddow, J E ^a   Lambert Messerlian, G M ^b  

^a FOUNDATION FOR BLOOD RESEARCH   (United States)

^b WOMEN AND INFANTS HOSPITAL   (United States)

^c NONE

Author keywords

Assay comparison; Dimeric inhibin A; Down's syndrome

Indexed keywords

ALPHA FETOPROTEIN; CHORIONIC GONADOTROPIN; ESTRIOL; INHIBIN A;

ADULT; ARTICLE; BLOOD ANALYSIS; CASE CONTROL STUDY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CURVE FITTING; DIAGNOSTIC ACCURACY; DOWN SYNDROME; FEMALE; FREEZING; HUMAN; IMMUNOASSAY; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; PERFORMANCE; PRENATAL SCREENING; STATISTICAL ANALYSIS; THAWING; THIRD TRIMESTER PREGNANCY; VALIDATION PROCESS;

ADULT; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; DIMERIZATION; DOWN SYNDROME; FEMALE; HUMANS; INHIBINS; MASS SCREENING; PREDICTIVE VALUE OF TESTS; PREGNANCY; PREGNANCY TRIMESTER, SECOND; PRENATAL DIAGNOSIS;

EID: 0035012545     PISSN: 09691413     EISSN: None     Source Type: Journal    
DOI: 10.1136/jms.8.1.2     Document Type: Article

References (36)

1. 1 Palomaki GE, Knight GJ, McCarthy JE, et al. Maternal serum screening for Down's syndrome in the United States: a 1995 survey. Am J Obstet Gynecol 1997;176:1046-51.
2. 2 Foundation for Blood Research/College of American Pathologists Maternal Serum Screening Survey. Waukegan, Illinois: College of American Pathologists, Set FP-A, 2000.
3. 3 Wald NJ, Cuckle HS, Densem JW, et al. Maternal serum screening for Down's syndrome in early pregnancy. BMJ 1988;297:883-7.
4. 4 Haddow JE, Palomaki GE, Knight GJ, et al. Prenatal screening for Down's syndrome with use of maternal serum markers. N Engl J Med 1992;327:588-93.
5. 5 Wald NJ, Kennard A, Hackshaw A, et al. Antenatal screening for Down's syndrome. J Med Screen 1997;4:181-246.
6. 6 Haddow JE, Palomaki GE, Knight GJ, et al. Second trimester screening for Down's syndrome using maternal serum dimeric inhibin A. J Med Screen 1998;5:115-19.
7. 7 Cuckle HS, Holding S, Jones R, et al. Maternal serum dimeric inhibin A in second-trimester Down's syndrome pregnancies. Prenat Diagn 1995;15:385-6.
8. 8 Lambert-Messerlian GM, Canick JA, Palomaki GE, et al. Second trimester levels of maternal serum inhibin-A, total inhibin, inhibin precursor and activin in Down's syndrome pregnancies. J Med Screen 1996;3:38-62.
9. 9 Wald N, Densem J, George L, et al. Prenatal screening for Down's syndrome using inhibin-A as a serum marker. Prenat Diagn 1996;16;143-53.
10. 10 Aitken DA, Wallace EM, Crossley JA, et al. Dimeric inhibin as a marker for Down's syndrome in early pregnancy. N Engl J Med 1996;334:1231-6.
11. 11 Illingworth PJ, Groome NP, Duncan WC, et al. Measurement of circulating inhibin forms during the establishment of pregnancy. J Clin Endrocrinol Metab 1996;81:1471-5.
12. 12 Fowler PA, Evans LW, Groome NP et al. A longitudinal study of maternal serum inhibin-A, inhibin-B, activin-A, activin-AB, pro-C, and follistatin during pregnancy. Hum Reprod 1998;13:3530-6.
13. 13 Robertson DM, Giacometti M, Foulds LM, et al. Isolation of inhibin subunit precursor proteins from bovine follicular fluid. Endocrinology 1989;125:2141-9.
14. 14 Schneyer AL, Mason AJ, Burton LE, et al. Immunoreactive inhibin alpha-subunit in human serum: implications for radioimmunoassay. J Clin Endocrinol Metab 1990;70:1208-12.
15. 15 Van Lith JMM, Pratt JJ, Beekhuis JR, et al. Second trimester maternal serum immunoreactive inhibin as a marker for fetal Down's syndrome. Prenat Diagn 1992;12:801-6.
16. 16 Spencer K, Wood PJ, Anthony FW. Elevated levels of maternal serum inhibin immunoreactivity in second trimester pregnancies affected by Down's syndrome. Ann Clin Biochem 1993;30:219-20.
17. 17 Cuckle HS, Holding S, Jones R. Maternal serum inhibin levels in second trimester Down's syndrome pregnancies. Prenat Diagn 1994;14:387-90.
18. 18 Groome NP, Hancock J, Betteridge A, et al. Monoclonal and polyclonal antibodies reactive with the 1-32 amino-terminal peptide of the alpha subunit of human inhibin. Hybridoma 1990;9:31-42.
19. 19 Groome NP, Illingworth PJ, O'Brien M, et al. Detection of dimeric inhibin throughout the human menstrual cycle. Clin Endocrinol 1994;40:717-23.
20. 20 Groome NP, Lawrence M. Preparation of monoclonal antibodies reactive with the beta A subunit of human ovarian inhibin. Hybridoma 1991;10:309-16.
21. 21 Wallace EM, Swanston IA, McNeilly AS, et al. Second trimester screening for Down's syndrome using maternal serum dimeric inhibin A. Clin Endocrinol 1996;44: 17-21.
22. 22 Wenstrom KD, Owen J, Chu DC, et al. Elevated second-trimester dimeric inhibin A levels identify Down's syndrome pregnancies. Am J Obstet Gynecol 1997;177:992-6.
23. 23 Knight PG, Muttukrishna S. Measurement of dimeric inhibin using a modified two-site immunoradiometric assay specific for oxidized (Met O) inhibin. J Endocrinol 1994;141:417-25.
24. 24 Lambert GM, Hall JE, Sluss PM, et al. Relatively low levels of dimeric inhibin circulate in men and women with polycystic ovarian syndrome using a specific two-site ELISA. J Clin Endocrinol Metab 1994;79:45-50.
25. 25 Mistry JS, Bodani U, Diamandis M, et al. A direct immunoassay for the quantitative determination of human inhibin-A. Clin Chem 2000;46(suppl 6):A129.
26. 26 Hayes FJ, Mistry J, Khosravi J, et al. Characterization of a new method for measurement of dimeric inhibin A in human serum. International Workshop on Inhibits, Activins, and Follistatins. Monash Medical Centre, Clayton, Australia, October 26-28, 2000.
27. 27 Haddow JE, Palomaki GE, Knight GJ, et al. Reducing the need for amniocentesis in women 35 years of age or older with serum markers for screening. N Engl J Med 1994;330: 114-18.
28. 28 Bland JM, Altman DG, Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 1986;i:307-10.
29. 29 Neveux LM, Palomaki GE, Larrivee DA, et al. Refinements in managing maternal weight adjustment for interpreting prenatal screening results. Prenat Diagn 1996;16:1115-19.
30. 30 Wald NJ, Densem JW, George L, et al. Inhibin-A in Down's syndrome pregnancies: revised estimate of standard deviation. Prenat Diagn 1997;17:285-90.
31. 31 Knight GJ, Palomaki GE, Neveux LM, et al. hCG and the free β-subunit as screening test for Down's syndrome. Prenat Diagn 1998;18:235-45.
32. 32 National Center for Health Statistics, Vital statistics of the United States, 1993, Vol 1. Natality. Washington DC: Government Printing Office, 1997:103 (DHHS publication No. 1 (PHS) 97).
33. 33 Royston P, Thompson SG. Model-based screening by risk with application to Down's syndrome. Stat Med 1992;11: 257-68.
34. 34 Wallace EM, Crossley JA, Ritoe SC, et al. Evolution of an inhibin A ELISA method: implications for Down's syndrome screening. Ann Clin Biochem 1998;35:656-64.
35. 35 Groome NP, Illingworth PJ, O'Brien M, et al. Detection of dimeric inhibin throughout the human menstrual cycle by two-site enzyme immunoassay. Clin Endocrinol 1994;40: 717-23.
36. 36 Anderson R, Khosravi MJ, Diamandis A, et al. The effect of endogenous substances, specimen type and analyte stability on the quantitative determination of inhihin-A with the DSL Active Inhibin-A ELISA. Clin Chem 2000;46(suppl 6):A41.